According to Chris Viehbacher, CEO Sanofi, India is the place to be for Sanofi to capture 40% of its sales from emerging markets by 2015 -- as compared to only 29% now. Thus, Sanofi acquired Shantha Biotech for 550 M euros in 2009, and plans to invest another 220 M euros in a new Hyderabad vaccine facility. The facility -- touted to be Asia's largest -- is slated to open its doors by March 2012.
Sanofi is targeting vaccines as one of its 6 key initiatives to help replace the 1/3 of its sales and 50% of its profits that it will be losing through patent expirations. One of the other key initiatives is to grow fast in the emerging markets. So building a new vaccine plant in India couples growth plans between vaccines and emerging markets. See European Biotechnology News.
Posted by Bruce Lehr Oct 10th 2011.
Comments